An observational study in COVID, sponsored by Xijing Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Xijing Hospital · Observational
The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population
Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
People infected with COVID-19
Exclusion Criteria:
Other: No Interventions
No intervention
PBMC
When conducting blood sample analysis, we focus on separating and evaluating in detail the composition and counting of peripheral blood mononuclear cell (PBMC). This process involves identifying and quantifying various types of mononuclear cells in the sample, such as lymphocytes, monocytes, etc. These cells are crucial for understanding an individual's immune status. Through precise separation techniques and advanced cell analysis methods, we are able to obtain accurate and detailed reports on the classification and quantity of mononuclear cells.
Time frame: About two and a half years
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital